These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 29931471)
21. A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground. Srivastava S; Deshpande D; Pasipanodya JG; Thomas T; Swaminathan S; Nuermberger E; Gumbo T Clin Infect Dis; 2016 Nov; 63(suppl 3):S75-S79. PubMed ID: 27742637 [TBL] [Abstract][Full Text] [Related]
22. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments. Pasipanodya JG; Nuermberger E; Romero K; Hanna D; Gumbo T Clin Infect Dis; 2015 Aug; 61 Suppl 1():S10-7. PubMed ID: 26224767 [TBL] [Abstract][Full Text] [Related]
23. Interaction index and different methods for determining drug interaction in combination therapy. Lee JJ; Kong M; Ayers GD; Lotan R J Biopharm Stat; 2007; 17(3):461-80. PubMed ID: 17479394 [TBL] [Abstract][Full Text] [Related]
24. Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model. Siopi M; Siafakas N; Vourli S; Zerva L; Meletiadis J Antimicrob Agents Chemother; 2015 Jul; 59(7):3973-83. PubMed ID: 25896699 [TBL] [Abstract][Full Text] [Related]
25. The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs. Bax HI; Bakker-Woudenberg IAJM; de Vogel CP; van der Meijden A; Verbon A; de Steenwinkel JEM Tuberculosis (Edinb); 2017 Jul; 105():80-85. PubMed ID: 28610791 [TBL] [Abstract][Full Text] [Related]
26. Quantitative assessment of the activity of antituberculosis drugs and regimens. Chirehwa MT; Velásquez GE; Gumbo T; McIlleron H Expert Rev Anti Infect Ther; 2019 Jun; 17(6):449-457. PubMed ID: 31144539 [No Abstract] [Full Text] [Related]
30. Effect of combined therapy of oral anti-tubercular agents on theophylline pharmacokinetics. Ahn HC; Yang JH; Lee HB; Rhee YK; Lee YC Int J Tuberc Lung Dis; 2000 Aug; 4(8):784-7. PubMed ID: 10949332 [TBL] [Abstract][Full Text] [Related]
31. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070 [TBL] [Abstract][Full Text] [Related]
32. Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs. Davies G; Boeree M; Hermann D; Hoelscher M PLoS Med; 2019 Jul; 16(7):e1002851. PubMed ID: 31287813 [TBL] [Abstract][Full Text] [Related]
33. Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. Ferro BE; Meletiadis J; Wattenberg M; de Jong A; van Soolingen D; Mouton JW; van Ingen J Antimicrob Agents Chemother; 2016 Feb; 60(2):1097-105. PubMed ID: 26643335 [TBL] [Abstract][Full Text] [Related]
34. Antimicrobial combinations: Bliss independence and Loewe additivity derived from mechanistic multi-hit models. Baeder DY; Yu G; Hozé N; Rolff J; Regoes RR Philos Trans R Soc Lond B Biol Sci; 2016 May; 371(1695):. PubMed ID: 27160596 [TBL] [Abstract][Full Text] [Related]
35. Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. Tam VH; Schilling AN; Lewis RE; Melnick DA; Boucher AN Antimicrob Agents Chemother; 2004 Nov; 48(11):4315-21. PubMed ID: 15504858 [TBL] [Abstract][Full Text] [Related]
36. Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity. Davies GR Tuberculosis (Edinb); 2010 May; 90(3):171-6. PubMed ID: 20382567 [TBL] [Abstract][Full Text] [Related]
37. Advances in clinical trial design: Weaving tomorrow's TB treatments. Lienhardt C; Nunn A; Chaisson R; Vernon AA; Zignol M; Nahid P; Delaporte E; Kasaeva T PLoS Med; 2020 Feb; 17(2):e1003059. PubMed ID: 32106220 [TBL] [Abstract][Full Text] [Related]
38. Emerging drugs and alternative possibilities in the treatment of tuberculosis. Hofman S; Segers MM; Ghimire S; Bolhuis MS; Sturkenboom MG; Van Soolingen D; Alffenaar JW Expert Opin Emerg Drugs; 2016; 21(1):103-16. PubMed ID: 26848966 [TBL] [Abstract][Full Text] [Related]
39. Mathematical modeling and systems pharmacology of tuberculosis: Isoniazid as a case study. Lalande L; Bourguignon L; Maire P; Goutelle S J Theor Biol; 2016 Jun; 399():43-52. PubMed ID: 27059890 [TBL] [Abstract][Full Text] [Related]